# James Larkin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-larkin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 133,749 |
| Field | Melanoma and MAPK Pathways |
| h-index | 130 |
| i10-index | 562 |
| Last Known Institution | University of California, Los Angeles |
| OpenAlex ID | https://openalex.org/A5076054848 |
| ORCID iD | https://orcid.org/0000-0001-5569-9523 |
| Works | 1,398 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition](https://scholariq.org/papers/meta-analysis-of-tumor-and-t-cell-intrinsic-mechanisms-of-sensitization-to/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.